AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18405786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (75, 100, 150, or 200 microg)
Number of subjects: 24
Study 18405786 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (75, 100, 150, or 200 microg)
Number of subjects: 24
Study 15724848 — intervention group
Group type: EXPERIMENTAL
Intervention: New examination system (workload-capability model)
Number of subjects: 0
Study 15724848 — intervention group
Group type: COMPARATOR
Intervention: Old examination system (diagnosis-focused)
Number of subjects: 0
Study 14674737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Healthy Directions study)
Number of subjects: 0
Study 14674737 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10839333 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (150 to 600 mg/d)
Number of subjects: 12
Study 10839333 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (single dose)
Number of subjects: 12
Study 10839333 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 12
Study 8676807 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) supplemented with ketoacids
Number of subjects: 12
Study 8676807 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (LPD) without ketoacids
Number of subjects: 12
Study 8676807 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD)
Number of subjects: 12
Study 1466184 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% urea cream (HTH lotion 'light')
Number of subjects: 47
Study 1466184 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% urea cream (HTH lotion 'Original')
Number of subjects: 47
Study 1466184 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (contralateral forearm)
Number of subjects: 47
Study 6732409 — intervention group
Group type: EXPERIMENTAL
Intervention: Large adult cuff
Number of subjects: 470
Study 6732409 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh cuff
Number of subjects: 470
Study 6732409 — intervention group
Group type: COMPARATOR
Intervention: Standard cuff
Number of subjects: 470
Study 30811460 — intervention group
Group type: EXPERIMENTAL
Intervention: Training seminar for clinicians
Number of subjects: 178
Study 30811460 — intervention group
Group type: COMPARATOR
Intervention: Post-seminar support and mentoring
Number of subjects: 178
Study 29381650 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (14 repeats of 20‐s swimming session with 10‐s pause between sessions, 4 d·wk for 6 wk)
Number of subjects: 21
Study 29381650 — intervention group
Group type: EXPERIMENTAL
Intervention: AT (treadmill running, 60 min at 30 m·min, 5 d·wk for 8 wk)
Number of subjects: 21
Study 29381650 — intervention group
Group type: COMPARATOR
Intervention: CON (sedentary control)
Number of subjects: 21
Study 26760604 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon catheter
Number of subjects: 158
Study 26760604 — intervention group
Group type: COMPARATOR
Intervention: Basket catheter
Number of subjects: 158
Study 24470557 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day) and temsirolimus (50 mg weekly, adjusted based on toxicities)
Number of subjects: 69
Study 24470557 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day) and temsirolimus (maximum tolerated dosage of 15 mg weekly)
Number of subjects: 69
Study 21717120 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-powered (AP) handcycling
Number of subjects: 12
Study 21717120 — intervention group
Group type: COMPARATOR
Intervention: Arm-trunk-powered (ATP) handcycling
Number of subjects: 12
Study 19913323 — intervention group
Group type: EXPERIMENTAL
Intervention: Viramidine 600 mg twice daily
Number of subjects: 962
Study 19913323 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin (1000 or 1200 mg/day based on weight)
Number of subjects: 962
Study 17868354 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture (according to TCM) plus Rizatriptan
Number of subjects: 160
Study 17868354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritualized mock acupuncture plus Rizatriptan
Number of subjects: 160
Study 17868354 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard mock acupuncture plus Rizatriptan
Number of subjects: 160
Study 17868354 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic treatment with relief therapy only (Rizatriptan)
Number of subjects: 160
Study 15507508 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplement (Ca-suppl.) of 850 mg/d
Number of subjects: 144
Study 15507508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 15507508 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplement (Ca-suppl.)
Number of subjects: 144
Study 12885714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways study intervention for primary prevention of obesity
Number of subjects: 1704
Study 11220353 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 365
Study 11220353 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 365
Study 8857857 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing diet (IED) - Immun‐Aid, McGaw, Inc., Irvine, CA; n = 17
Number of subjects: 35
Study 8857857 — intervention group
Group type: COMPARATOR
Intervention: Isonitrogenous, isocaloric diet - Promote (Ross Laboratories, Columbus, OH) and Casec (Mead‐Johnson Nutritionals, Evansville, IN); n = 18
Number of subjects: 35
Study 8857857 — intervention group
Group type: COMPARATOR
Intervention: Unfed controls; n = 19
Number of subjects: 35
Study 1518261 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (9 different intensive chemotherapy regimens)
Number of subjects: 39
Study 1518261 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular maintenance therapy
Number of subjects: 39
Study 1518261 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 39
Study 1518261 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous BMT
Number of subjects: 39
Study 1518261 — intervention group
Group type: COMPARATOR
Intervention: No therapy or palliative therapy
Number of subjects: 39
Study 1518261 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation in relapse
Number of subjects: 39
Study 6222590 — intervention group
Group type: EXPERIMENTAL
Intervention: Hansson nail (less traumatizing cylindric nail)
Number of subjects: 82
Study 6222590 — intervention group
Group type: COMPARATOR
Intervention: Rydell nail (four-flanged nail)
Number of subjects: 82
Study 29393147 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk
Number of subjects: 9
Study 29393147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free milk
Number of subjects: 9
Study 29393147 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study 27306628 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 20 mg orally every week
Number of subjects: 50
Study 27306628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27306628 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 50
Study 26205962 — intervention group
Group type: EXPERIMENTAL
Intervention: CRM team leader training (CRM-TL)
Number of subjects: 180
Study 26205962 — intervention group
Group type: COMPARATOR
Intervention: Additional ALS training (ALS add-on)
Number of subjects: 180
Study 23803881 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic index meal
Number of subjects: 12
Study 23803881 — intervention group
Group type: COMPARATOR
Intervention: Low-glycemic index meal
Number of subjects: 12
Study 21119130 — intervention group
Group type: EXPERIMENTAL
Intervention: Breeze Self-Adhesive Resin Cement
Number of subjects: 20
Study 21119130 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem Self-Adhesive Universal Resin Cement
Number of subjects: 20
Study 21119130 — intervention group
Group type: COMPARATOR
Intervention: RelyX ARC Adhesive Resin Cement
Number of subjects: 20
Study 18925348 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggression-prevention treatment (specific details not provided)
Number of subjects: 489
Study 16897918 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer administration of the CTS with increased minimum item display duration
Number of subjects: 0
Study 16897918 — intervention group
Group type: COMPARATOR
Intervention: Hierarchical order presentation of CTS items
Number of subjects: 0
Study 16897918 — intervention group
Group type: COMPARATOR
Intervention: Interspersed order presentation of CTS items
Number of subjects: 0
Study 12837139 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 to 10 mg/day)
Number of subjects: 84
Study 10648297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 31
Study 10648297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8888803 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmofur (HCFU) for 1 year
Number of subjects: 173
Study 8888803 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no HCFU
Number of subjects: 173
Study 1913758 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal stimulation (alternating warm and cool immersion) at frequencies of 0.013‐0.096 Hz and stimulus amplitude exceeding 10 degrees C.
Number of subjects: 18
Study 1913758 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (mean temperature of 23‐33 degrees C).
Number of subjects: 18
Study 1913758 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal stimulation of the sitting subjects' forearm instead of legs.
Number of subjects: 18
Study 1913758 — intervention group
Group type: COMPARATOR
Intervention: Thermal stimulation and sham stimulation.
Number of subjects: 18
Study 1913758 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cooling of the stimulated lower legs.
Number of subjects: 18
Study 6689091 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g of dazoxiben
Number of subjects: 24
Study 6689091 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 g or 1.0 g of acetylsalicylic acid (ASA)
Number of subjects: 24
Study 6689091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30557128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 363
Study 30557128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Number of subjects: 363
Study 30557128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (both IXEQ4W and IXEQ2W)
Number of subjects: 363
Study 30557128 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 363
Study 30004001 — intervention group
Group type: EXPERIMENTAL
Intervention: Procera® crowns
Number of subjects: 27
Study 30004001 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS e.max Press crowns
Number of subjects: 27
Study 30004001 — intervention group
Group type: EXPERIMENTAL
Intervention: Crown therapy (both types)
Number of subjects: 27
Study 30004001 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 27
Study 25017958 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP
Number of subjects: 120
Study 23009873 — intervention group
Group type: COMPARATOR
Intervention: 500 mg oral ciprofloxacin twice daily for 1 day before and for 2 days after biopsy (group 1)
Number of subjects: 1197
Study 23009873 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg intravenous amikacin 30 minutes before biopsy plus 500 mg oral ciprofloxacin (group 2)
Number of subjects: 1197
Study 21753203 — intervention group
Group type: EXPERIMENTAL
Intervention: SAB0.3 (0.03% sorbic acid blend)
Number of subjects: 225
Study 21753203 — intervention group
Group type: EXPERIMENTAL
Intervention: SAB1 (0.1% sorbic acid blend)
Number of subjects: 225
Study 21753203 — intervention group
Group type: EXPERIMENTAL
Intervention: SAB5 (0.5% sorbic acid blend)
Number of subjects: 225
Study 21753203 — intervention group
Group type: EXPERIMENTAL
Intervention: SAB0.2 (0.2% sorbic acid blend)
Number of subjects: 225
Study 21753203 — intervention group
Group type: COMPARATOR
Intervention: Negative control (not challenged and not treated)
Number of subjects: 225
Study 21753203 — intervention group
Group type: COMPARATOR
Intervention: Positive control (challenged and not treated)
Number of subjects: 225
Study 21753203 — intervention group
Group type: COMPARATOR
Intervention: Control (not treated)
Number of subjects: 225
Study 18647851 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 24
Study 17365266 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% dithranol lipogel
Number of subjects: 20
Study 17365266 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cream containing 1.15% dithranol, 1.15% salicylic acid and 5.3% coal tar
Number of subjects: 20
Study 17365266 — intervention group
Group type: COMPARATOR
Intervention: Liposomal base
Number of subjects: 20
Study 15028558 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 990
Study 15028558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 990
Study 15028558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 990
Study 11772135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg plus pseudoephedrine SR 120 mg twice daily for 2 to 3 weeks
Number of subjects: 0
Study 9551285 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 0
Study 8746927 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate (150 mg/week for two weeks, 300 mg/week for two weeks, and 600 mg/week for two weeks)
Number of subjects: 8
Study 8746927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2183732 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clindamycin hydrochloride
Number of subjects: 56
Study 2183732 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cephalexin
Number of subjects: 56
Study 342797 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of strophanthin and glucagon
Number of subjects: 0
Study 342797 — intervention group
Group type: COMPARATOR
Intervention: Isolated use of strophanthin
Number of subjects: 0
Study 342797 — intervention group
Group type: COMPARATOR
Intervention: Isolated use of glucagon
Number of subjects: 0
Study 31767470 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated CHARTWEL schedule
Number of subjects: 146
Study 31767470 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 146
Study 31767470 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARTWEL
Number of subjects: 146
Study 30685773 — intervention group
Group type: EXPERIMENTAL
Intervention: Living within 500 meters of high voltage power lines
Number of subjects: 933
Study 30685773 — intervention group
Group type: EXPERIMENTAL
Intervention: Living between 500-1000 meters of high voltage power lines
Number of subjects: 933
Study 30685773 — intervention group
Group type: COMPARATOR
Intervention: Living more than 1000 meters away from high voltage power lines
Number of subjects: 933
Study 30685773 — intervention group
Group type: EXPERIMENTAL
Intervention: Living within 500 meters of high voltage power lines (adjusted for confounding factors)
Number of subjects: 933
Study 26429571 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D3 supplementation (20,000 IU/week)
Number of subjects: 68
Study 26429571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 26429571 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients on immunomodulatory therapy
Number of subjects: 68
Study 26429571 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 68
Study 26429571 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy
Number of subjects: 68
Study 23835139 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation over six sessions plus treatment as usual (TAU) (n=19)
Number of subjects: 34
Study 23835139 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone (n=15)
Number of subjects: 34
Study 21787048 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture Exchange Communication System (PECS) training
Number of subjects: 84
Study 19323939 — intervention group
Group type: EXPERIMENTAL
Intervention: DB ACL reconstruction
Number of subjects: 64
Study 19323939 — intervention group
Group type: COMPARATOR
Intervention: SB ACL reconstruction
Number of subjects: 64
Study 17060265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual atropine for 48 hours
Number of subjects: 22
Study 17060265 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 48 hours
Number of subjects: 22
Study 17060265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual atropine
Number of subjects: 22
Study 17060265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 14965832 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Conformal radiotherapy (CRT) with a total dose of 45-54 Gy given in 8-12 fractions completed in 18-27 days
Number of subjects: 67
Study 14965832 — intervention group
Group type: COMPARATOR
Intervention: Group B: Conformal radiotherapy (CRT) with a total dose of 45-54 Gy in 15-18 fractions within 20-25 days
Number of subjects: 67
Study 11686867 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble recombinant IL-4 receptor (IL-4 antagonist)
Number of subjects: 0
Study 9197292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 73
Study 9197292 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 73
Study 1406473 — intervention group
Group type: EXPERIMENTAL
Intervention: Broviac-type 'life-cath' and Groshong-catheter
Number of subjects: 160
Study 1406473 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral therapy
Number of subjects: 160
Study 1406473 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter removal due to end of therapy
Number of subjects: 160
Study 1406473 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-related complications
Number of subjects: 160
Study 1406473 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion of the lumen
Number of subjects: 160
Study 1406473 — intervention group
Group type: EXPERIMENTAL
Intervention: Explantation due to suspected catheter-related sepsis
Number of subjects: 160
Study 1406473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative patency rate
Number of subjects: 160
Study 1406473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative rate of functioning catheters
Number of subjects: 160
Study 1406473 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 160
Study 4019266 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression method
Number of subjects: 30
Study 4019266 — intervention group
Group type: COMPARATOR
Intervention: Shield method
Number of subjects: 30
Study 30289365 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol (FC, n=40)
Number of subjects: 58
Study 30289365 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol-Tetracycline-Zinc Oxide-Eugenol (CTZ, n=40)
Number of subjects: 58
Study 29169668 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression
Number of subjects: 313
Study 29169668 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational arthroscopy only
Number of subjects: 313
Study 29169668 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 313
Study 26645538 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS monitoring with treatment guideline intervention
Number of subjects: 67
Study 26645538 — intervention group
Group type: COMPARATOR
Intervention: No action taken on alarms
Number of subjects: 67
Study 24974353 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 111
Study 24974353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 22378112 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen cross-linking (CXL) with riboflavin and UV irradiation
Number of subjects: 14
Study 19427680 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAMTS13 900V variant
Number of subjects: 560
Study 19427680 — intervention group
Group type: COMPARATOR
Intervention: ADAMTS13 Q448E
Number of subjects: 560
Study 19427680 — intervention group
Group type: COMPARATOR
Intervention: ADAMTS13 P618A
Number of subjects: 560
Study 17963428 — intervention group
Group type: COMPARATOR
Intervention: Prulifloxacin 600 mg tablet administered 3 hours before surgery (Group B)
Number of subjects: 20
Study 17963428 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily for 3 days (Group C)
Number of subjects: 20
Study 16225568 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (114.75 mg intravenous infusion) + Labetalol (100 mg orally twice daily)
Number of subjects: 32
Study 16225568 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (114.75 mg intravenous infusion) + Betamethasone (12 mg intramuscular injection)
Number of subjects: 32
Study 16225568 — intervention group
Group type: COMPARATOR
Intervention: Atosiban (114.75 mg intravenous infusion)
Number of subjects: 32
Study 16225568 — intervention group
Group type: COMPARATOR
Intervention: Labetalol (100 mg orally twice daily)
Number of subjects: 32
Study 16225568 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone (12 mg intramuscular injection)
Number of subjects: 32
Study 12698990 — intervention group
Group type: EXPERIMENTAL
Intervention: FMI (final market image) tablet formulation of oxcarbazepine
Number of subjects: 0
Study 9698695 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual numerical clinical targets
Number of subjects: 0
Study 9698695 — intervention group
Group type: COMPARATOR
Intervention: No targets
Number of subjects: 0
Study 9698695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (target and no-target)
Number of subjects: 0
Study 9698695 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting of clinical targets
Number of subjects: 0
Study 8657506 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U/kg rHuEPO biweekly
Number of subjects: 19
Study 8657506 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 U/kg rHuEPO biweekly
Number of subjects: 19
Study 8657506 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation 10 mg/kg/week intravenously
Number of subjects: 19